Enoxaparin sensitizes human non-small-cell lung carcinomas to gefitinib by inhibiting DOCK1 expression, vimentin phosphorylation, and Akt activation. [electronic resource]
Producer: 20150320Description: 378-90 p. digitalISSN:- 1521-0111
- Animals
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Cell Line, Tumor
- Enoxaparin -- administration & dosage
- Gefitinib
- Gene Expression Regulation, Neoplastic
- Humans
- Lung Neoplasms -- drug therapy
- Mice
- Mice, Inbred BALB C
- Mice, Nude
- Phosphorylation -- drug effects
- Proto-Oncogene Proteins c-akt -- antagonists & inhibitors
- Quinazolines -- administration & dosage
- Vimentin -- antagonists & inhibitors
- Xenograft Model Antitumor Assays -- methods
- rac GTP-Binding Proteins -- antagonists & inhibitors
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.